In Heidelberg alone, more than 500 biomedical research groups are constantly generating innovation. In BioRN’s extended, European network it is more than 2500 groups which, together with about 1800 German biotech companies and start-ups, represent a vast source of opportunities for healthcare companies to meet all their partnering, investment and licensing needs. However, identifying the best matches and keeping track of fast-moving scientific developments for all these innovators in different regions is difficult and highly resource intensive, especially without sufficient embedding in regional networks.
Our strong and manifold ties to all regional and national stakeholders and via Health Axis Europe to additional life science clusters in Leuven, Maastricht and Copenhagen moreover allows us to detect very early-stage projects first and to score hits which usually would stay off-radar.
HAEP is currently running in a BMBF funded two-year validation phase